FDA Calls for More Data on Dupilumab for CSU Indication : vi

In a letter, the FDA stated that additional efficacy data are required to support an approval for chronic spontaneous urticaria (CSU), according to the manufacturers of dupilumab.

Related Keywords

Berlin , Germany , United States , American , Omalizumab Xolair , Dupilumab Dupixent , Drug Administration , American Academy Of Allergy , European Academy Of Dermatology , European Academy , Urticaria , Angioedema , Lives , Biologic Therapy , Antihistamine , Pruritus , Pruritis , Pitch , Quality Of Life , Pol , Ealth Related Quality Of Life , Rqol , Asthma , Sthmatic , Anti Immunoglobulin E , Nti Ige , Allergy , Clinical Research , Clinical Trials , Linical Studies , Europe , European , Us Food And Drug Administration , Nited States Food And Drug Administration , Fda , The ,